Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097188
Status:
COMPLETED
Last Update Posted:
2014-03-04
First Post:
2004-11-18
Brief Title:
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase II Randomized Double-Blind Parallel-Group Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Rituximab MabtheraRituxan in Adults With Relapsing Remitting Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II randomized double-blind parallel group placebo controlled multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None